How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The "forgotten adjunct therapy": the link between ESA use and control of hyperparathyroidism in chronic kidney disease.

Christopher T Chan, Marisa Battistella

Journal: Seminars in dialysis 2014;26(5):537-40

PMID: 23734745

Abstract

Address: From Division of Nephrology, University Health Network, Toronto, Ontario, Canada.

Medical:

Other Literature Sources:

Full Text Sources:

MeSH Terms: Anemia, Iron-Deficiency, Bone Density, Darbepoetin alfa, Drug Resistance, Erythropoietin, Hematinics, Humans, Hyperparathyroidism, Renal Dialysis, Renal Insufficiency, Chronic